Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Triple negative
•
Breast Cancer, Metastatic
What initial treatment would you offer a patient with metastatic triple negative breast cancer with somatic BRCA1/2 mutation, CPS <10?
Is there a role of olaparib in light of TBCRC 048 data showing response in somatic mutations?
Related Questions
In what situations would you consider doublet chemotherapy in treatment of a premenopausal de novo metastatic TNBC?
How are you requesting testing for HER2-ultralow status, in light of DB-06 trial demonstrating benefit of T-DXd for these patients?
Is there benefit of cold-cap use while patient is on sacituzumab-govitecan?
How do the findings from the INAVO120 trial influence your decision-making process for selecting subsequent lines of therapy in patients who have relapsed after adjuvant CDK4/6 inhibition?
What is your experience and treatment efficacy of tucatinib if used after enhertu in metastatic breast cancer?
Is there a correlation with severity of rash as an adverse event and response rate with capivasertib?
For patients with HbA1c >6 can the INAVO regimen still be utilized if the patient is otherwise fit and has a strategy for ongoing glycemic control?
For patients with PI3K mutated metastatic breast cancer who progress on a PI3K inhibitor, will you use an alternative PI3K inhibitor subsequently?
How do you reconcile data from PATINA trial and DESTINY-Breast09 with respect to CDK4/6 inhibitor maintenance in metastatic HER 2+ breast cancer?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?